查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586058

癌症疫苗市场：按技术、治疗方法和应用分类 - 2025-2030 年全球预测

Cancer Vaccines Market by Technology (Antigen, Dendritic Cells, Recombinant Cancer Vaccines), Treatment Method (Preventive Vaccine, Therapeutic Vaccine), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年癌症疫苗市值为179亿美元，预计2024年将达205.6亿美元，复合年增长率为15.37%，到2030年将达到487.1亿美元。

癌症疫苗代表了肿瘤学在预防和治疗应用方面的关键进步。这些疫苗刺激人体的免疫系统辨识和消灭癌细胞，防止高危险群发生癌细胞或治疗现有的恶性。癌症疫苗具有广泛的靶点，针对子宫颈癌、肝癌和胃癌等多种癌症，并受到免疫治疗意识增强和技术创新的推动。这种需求源于癌症发病率的不断上升，这推动了对更有针对性和更有效的治疗方法的需求。主要用途包括预防性疫苗（例如人类乳突病毒(HPV)疫苗）和抑制癌症（例如黑色素瘤）復发和转移的治疗型疫苗。最终用途包括医院、癌症研究机构和癌症诊所，主要市场在美国、欧洲和亚太地区。

主要市场统计
基准年[2023] 179亿美元
预测年份 [2024] 205.6亿美元
预测年份 [2030] 487.1亿美元
复合年增长率（%） 15.37%

确定了关键的成长要素，包括抗原发现的进步、生物技术研发投资的增加以及透过公私合营增加资金筹措。对个人化医疗的日益关注以及吸引精准治疗爱好者的基于新抗原的疫苗的开发已经成熟。创业家应该利用这些趋势，探索突破性疫苗试验的伙伴关係，并利用人工智慧来改善抗原辨识。然而，严格的监管条件、高昂的开发成本和有限的熟练人力资源等挑战构成了主要障碍。此外，漫长的临床试验过程和不同癌症类型的疗效差异也限制了市场的成长。

最具创新性的领域涉及探索将癌症疫苗与查核点抑制剂和其他免疫调节剂结合的联合治疗。专注于开发具有成本效益的疫苗生产流程可以缓解财务限制。透过利用基因组定序的进步，我们可以进一步个人化疫苗反应并改善患者的治疗结果。简而言之，癌症疫苗市场是动态的，只要能够有效克服障碍，就有可能透过创新和策略联盟显着成长。

市场动态：揭示快速发展的癌症疫苗市场的关键市场洞察

供需的动态交互作用正在改变癌症疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人口增加导致癌症患者增加
    • 提高患者对癌症治疗的认识
    • 人类乳突病毒 (HPV) 感染发生率增加
  • 市场限制因素
    • 开发成本高
  • 市场机会
    • 增加对癌症疫苗开发的投资和政府资助
    • 癌症疫苗技术开发
  • 市场挑战
    • 生产一种疫苗所需的时间长度

波特五力：驾驭癌症疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对癌症疫苗市场的影响

外部宏观环境因素在塑造癌症疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解癌症疫苗市场的竞争状况

癌症疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵癌症疫苗市场供应商绩效评估

FPNV定位矩阵是评估癌症疫苗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议描绘癌症疫苗市场的成功之路

癌症疫苗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于人口老化的增加，癌症患者数量增加
      • 提高患者对癌症治疗的认识
      • 人类乳突病毒 (HPV) 感染发生率增加
    • 抑制因素
      • 癌症疫苗研发成本高
    • 机会
      • 增加对癌症疫苗开发的投资和政府资助
      • 癌症疫苗的技术开发
    • 任务
      • 生产一种疫苗需要很长时间
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章癌症疫苗市场：依技术分类

  • 抗原
  • 树突状细胞
  • 重组癌症疫苗
  • 病毒载体和 DNA 癌症疫苗
  • 全细胞癌症疫苗

第七章依治疗方式分類的癌症疫苗市场

  • 预防性疫苗
  • 治疗性疫苗

第八章癌症疫苗市场：依应用分类

  • 子宫颈癌
  • 摄护腺癌

第九章美洲癌症疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区癌症疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲癌症疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Advaxis Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • Dynavax Technologies
  • GSK PLC
  • Helsinn Healthcare SA
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Sanpower Group Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA0514B

The Cancer Vaccines Market was valued at USD 17.90 billion in 2023, expected to reach USD 20.56 billion in 2024, and is projected to grow at a CAGR of 15.37%, to USD 48.71 billion by 2030.

Cancer vaccines represent a pivotal advancement in oncology, aimed at both prophylactic and therapeutic applications. These vaccines function by stimulating the body's immune system to identify and destroy cancer cells, either preventing onset in high-risk individuals or treating existing malignancies. The scope of cancer vaccines is broad, addressing various cancers such as cervical, liver, and gastric cancers, driven by heightened awareness and technological innovation in immunotherapy. Necessity arises from the growing cancer prevalence, driving demand for more targeted, effective treatment modalities. Key applications include preventive vaccines like the HPV vaccine and therapeutic types aiding in reducing recurrence and metastasis in cancers such as melanoma. The end-use scope spans hospitals, cancer research institutes, and specialized oncology clinics, with the U.S., Europe, and Asia-Pacific regions being critical markets.

KEY MARKET STATISTICS
Base Year [2023] USD 17.90 billion
Estimated Year [2024] USD 20.56 billion
Forecast Year [2030] USD 48.71 billion
CAGR (%) 15.37%

Insights reveal significant growth factors, including advancements in antigen discovery, rising investment in biotech R&D, and collaborations between public-private sectors enhancing funding. Opportunities are ripe in the growing focus on personalized medicine and the development of neoantigen-based vaccines, appealing to precision therapy enthusiasts. Entrepreneurs should explore partnerships for breakthrough vaccine trials and leverage AI for improved antigen identification to capitalize on these trends. However, challenges such as stringent regulatory landscapes, high development costs, and limited skilled personnel pose significant hurdles. Additionally, market growth is constrained by slow clinical trial processes and varying efficacy across cancer types.

The best innovation areas include exploring combination therapies integrating cancer vaccines with checkpoint inhibitors and other immunomodulatory agents. Emphasis on developing cost-effective vaccine manufacturing processes can mitigate financial restraints. Leveraging advancements in genome sequencing can further personalize vaccine responses, leading to better patient outcomes. In essence, the cancer vaccines market is dynamic, with vast potential for growth driven by innovation and strategic alliances, provided the barriers are effectively navigated.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Vaccines Market

The Cancer Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in number of cancer patients along with growing geriatric population
    • Surge in patient awareness towards cancer therapy
    • Increase in prevalence of human papilloma virus (HPV) infections
  • Market Restraints
    • High cost for developing cancer vaccines
  • Market Opportunities
    • Increase in investments and government funding in development of cancer vaccines
    • Technological developments in cancer vaccines
  • Market Challenges
    • Longer time span required for manufacturing a single vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Vaccines Market

A detailed market share analysis in the Cancer Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Vaccines Market

A strategic analysis of the Cancer Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Vaccines Market, highlighting leading vendors and their innovative profiles. These include Advaxis Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Celldex Therapeutics, Dynavax Technologies, GSK PLC, Helsinn Healthcare SA, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Sanpower Group Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Technology, market is studied across Antigen, Dendritic Cells, Recombinant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines, and Whole-cell Cancer Vaccines.
  • Based on Treatment Method, market is studied across Preventive Vaccine and Therapeutic Vaccine.
  • Based on Application, market is studied across Cervical Cancer and Prostate Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in number of cancer patients along with growing geriatric population
      • 5.1.1.2. Surge in patient awareness towards cancer therapy
      • 5.1.1.3. Increase in prevalence of human papilloma virus (HPV) infections
    • 5.1.2. Restraints
      • 5.1.2.1. High cost for developing cancer vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in investments and government funding in development of cancer vaccines
      • 5.1.3.2. Technological developments in cancer vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Longer time span required for manufacturing a single vaccine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Vaccines Market, by Technology

  • 6.1. Introduction
  • 6.2. Antigen
  • 6.3. Dendritic Cells
  • 6.4. Recombinant Cancer Vaccines
  • 6.5. Viral Vector & DNA Cancer Vaccines
  • 6.6. Whole-cell Cancer Vaccines

7. Cancer Vaccines Market, by Treatment Method

  • 7.1. Introduction
  • 7.2. Preventive Vaccine
  • 7.3. Therapeutic Vaccine

8. Cancer Vaccines Market, by Application

  • 8.1. Introduction
  • 8.2. Cervical Cancer
  • 8.3. Prostate Cancer

9. Americas Cancer Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Cancer Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Cancer Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advaxis Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Celldex Therapeutics
  • 6. Dynavax Technologies
  • 7. GSK PLC
  • 8. Helsinn Healthcare SA
  • 9. Johnson & Johnson
  • 10. Merck & Co., Inc.
  • 11. Novartis International AG
  • 12. Pfizer Inc.
  • 13. Sanofi SA
  • 14. Sanpower Group Co., Ltd.
  • 15. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER VACCINES MARKET SIZE, BY ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER VACCINES MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER VACCINES MARKET SIZE, BY RECOMBINANT CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER VACCINES MARKET SIZE, BY VIRAL VECTOR & DNA CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER VACCINES MARKET SIZE, BY WHOLE-CELL CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER VACCINES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CANCER VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY TREATMENT METHOD, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CANCER VACCINES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CANCER VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. CANCER VACCINES MARKET, FPNV POSITIONING MATRIX, 2023